Simple Summary Patients with high-risk neuroblastoma, especially those whose disease
either does not respond or recurs, have a poor chance of survival. Additionally, the majority …

Pediatric low-grade gliomas (pLGG) show heterogeneous responses to MAPK inhibitors
(MAPKi) in clinical trials. Thus, more complex stratification biomarkers are needed to identify …

As the mitogen-activated protein kinase (MAPK) signalling pathway is activated in many
paediatric cancers, it is an important therapeutic target. Currently, a range of targeted MAPK …

Abstract Background National Cancer Institute-Children's Oncology Group Pediatric
Molecular Analysis for Therapy Choice assigns patients aged 1-21 years with refractory …

Erdheim-Chester disease (ECD) and Rosai-Dorfman disease (RDD) are rare non-
Langerhans cell histiocytoses (non-LCHs), for which therapeutic options are limited. MAPK …

PURPOSE INFORM is an international pediatric precision oncology registry, prospectively
collecting molecular and clinical data of children with recurrent, progressive, or very high …

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas and the
primary cause of mortality in patients with neurofibromatosis type 1 (NF1). These …

PURPOSE The National Cancer Institute-Children's Oncology Group Pediatric Molecular
Analysis for Therapy Choice trial assigned patients age 1-21 years with relapsed or …

Large-scale tumor molecular profiling has revealed that diverse cancer histologies are
driven by common pathways with unifying biomarkers that can be exploited therapeutically …

In the past decade significant advancements have been made in the discovery of targetable
lesions in pediatric low-grade gliomas (pLGGs). These tumors account for 30-50% of all …